LARP4B, upregulated by METTL3-mediated, IGF2BP3-dependent m6A modification, promotes cancer stemness progression and impairs sorafenib efficacy by activating the SPINK1-mediated EGFR pathway. This evidence concerns the gene METTL3 and cancer.